000 | 05356cam a2200769Ii 4500 | ||
---|---|---|---|
001 | ocn729726279 | ||
003 | OCoLC | ||
005 | 20171224113647.0 | ||
006 | m o d | ||
007 | cr cn||||||||| | ||
008 | 110609s2011 gw a ob 001 0 eng d | ||
040 |
_aDG1 _beng _erda _epn _cDG1 _dYDXCP _dCDX _dOCLCQ _dE7B _dN$T _dSCB _dOCLCQ _dMHW _dOTZ _dIDEBK _dOCLCQ _dNLGGC _dOCLCQ _dCOO _dOCLCQ _dTMC _dD6H |
||
019 |
_a740225701 _a741454003 _a778454561 _a781264224 _a785512762 _a816845214 |
||
020 |
_a9783527635955 _q(electronic bk.) |
||
020 |
_a3527635955 _q(electronic bk.) |
||
020 |
_a9783527635979 _q(electronic bk.) |
||
020 |
_a3527635971 _q(electronic bk.) |
||
020 | _a1283140918 | ||
020 | _a9781283140911 | ||
020 |
_z9783527326969 _q(hbk.) |
||
020 |
_z3527326960 _q(hbk.) |
||
020 | _z9783527635962 | ||
020 | _z3527635963 | ||
020 | _z9783527635986 | ||
020 | _z352763598X | ||
024 | 8 | _a9786613140913 | |
029 | 1 |
_aAU@ _b000047551108 |
|
029 | 1 |
_aNZ1 _b14693860 |
|
029 | 1 |
_aNZ1 _b15915098 |
|
035 |
_a(OCoLC)729726279 _z(OCoLC)740225701 _z(OCoLC)741454003 _z(OCoLC)778454561 _z(OCoLC)781264224 _z(OCoLC)785512762 _z(OCoLC)816845214 |
||
037 |
_a10.1002/9783527635955 _bWiley InterScience _nhttp://www3.interscience.wiley.com |
||
050 | 4 |
_aRS431.A66 _bA68 2011 |
|
060 | 4 | _aQV268.5 | |
072 | 7 |
_aMED _x071000 _2bisacsh |
|
082 | 0 | 4 |
_a615.7924 _222 |
049 | _aMAIN | ||
245 | 0 | 0 |
_aAntiviral drug strategies / _cedited by Erik De Clercq. |
264 | 1 |
_aWeinheim : _bWiley-VCH ; _aChichester : _bJohn Wiley [distributor], _c2011. |
|
300 |
_a1 online resource (xx, 406 pages) : _billustrations (some color). |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
490 | 1 |
_aMethods and principles in medicinal chemistry ; _vv. 50 |
|
504 | _aIncludes bibliographical references and index. | ||
505 | 0 | 0 |
_tOutlook of the antiviral drug era, now more than 50 years after description of the first antiviral drug / _rErik De Clercq -- _tInhibition of HIV entry / _rJosé A. Esté -- _tTargeting integration beyond strand transfer: development of second-generation HIV integrase inhibitors / _rArnout R.D. Voet, _rMarc De Maeyer, _rFrauke Christ, _rZeger Debyser -- _tFrom saquinavir to darunavir: the impact of 10 years of medicinal chemistry on a lethal disease / _rMarie-Pierre de Béthune, _rAnik Peeters, _rPiet Wigerinck -- _tAcyclic and cyclic nucleoside phosphonates / _rRichard L. Mackman, _rTomas Cihlar -- _tHelicase-primase inhibitors: a new approach to combat herpes simplex virus and varicella zoster virus / _rSubhajit Biswas, _rHugh J. Field -- _tCyclophilin inhibitors / _rGrégoire Vuagniaux, _rArnaud Hamel, _rRafael Crabbé, _rHervé C. Porchet, _rJean-Maurice Dumont -- _tAlkoxyalkyl ester prodrugs of antiviral nucleoside phosphates and phosphonates / _rJames R. Beadle, _rKarl Y. Hostetler -- _tMaribavir: a novel benzimidazole ribonucleoside for the prevention and treatment of cytomegalovirus diseases / _rKaren K. Biron -- _tAnti-HCMV compounds / _rGraciela Andrei, _rRobert Snoeck -- _tLethal mutagenesis as an unconventional approach to combat HIV / _rPinar Iyidogan, _rKaren S. Anderson -- _tRecent progress in the development of HCV protease inhibitors / _rNagraj Mani, _rBhisetti G. Rao, _rTara L. Kieffer, _rAnn D. Kwong -- _tAntiviral RNAi: how to silence viruses / _rKarin J. von Eije, _rBen Berkhout -- _tNeuraminidase inhibitors as anti-influenza agents / _rWillard Lew, _rMichael Z. Wang, _rXiaowu Chen, _rJames F. Rooney, _rChoung Kim -- _tFrom TIBO to rilpivirine: the chronicle of the discovery of the ideal nonnucleoside reverse transcriptase inhibitor / _rErik De Clercq. |
588 | 0 | _aPrint version record. | |
520 | _aBy focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, this ready reference provides the critical knowledge needed to develop entirely novel therapeutics and to target new viruses. It begins with a general discussion of antiviral strategies, followed by a broad survey of known viral targets, such as reverse transcriptases, proteases, neuraminidases, RNA polymerases, helicases and primases, as well as their known inhibitors. The final section contains several cases studies of recent successful antiviral drug development. Edited by Erik de. | ||
650 | 0 |
_aAntiviral agents _xDevelopment. |
|
650 | 4 |
_aAntiviral agents _xDevelopment. |
|
650 | 7 |
_aMEDICAL _xPharmacology. _2bisacsh |
|
650 | 2 | _aAntiviral Agents. | |
650 | 2 | _aDrug Discovery. | |
655 | 4 | _aElectronic books. | |
700 | 1 | _aDe Clercq, Erik. | |
776 | 0 | 8 |
_iPrint version: _tAntiviral drug strategies. _dWeinheim : Wiley-VCH ; Chichester : John Wiley [distributor], 2011 _z9783527326969 _w(OCoLC)664325845 |
830 | 0 |
_aMethods and principles in medicinal chemistry ; _vv. 50. |
|
856 | 4 | 0 |
_uhttp://onlinelibrary.wiley.com/book/10.1002/9783527635955 _zWiley Online Library |
938 |
_aCoutts Information Services _bCOUT _n18076798 |
||
938 |
_aEBL - Ebook Library _bEBLB _nEBL693852 |
||
938 |
_aebrary _bEBRY _nebr10517364 |
||
938 |
_aEBSCOhost _bEBSC _n411148 |
||
938 |
_aIngram Digital eBook Collection _bIDEB _n314091 |
||
938 |
_aYBP Library Services _bYANK _n7279829 |
||
938 |
_aYBP Library Services _bYANK _n5559632 |
||
938 |
_aYBP Library Services _bYANK _n12679352 |
||
994 |
_a92 _bDG1 |
||
999 |
_c11141 _d11141 |